House of Commons – Feb. 9, 2026 – a.656.1.2
Backbench Business - Brain Tumour Survival RatesBackbench Business
Result
✅ Motion approved without vote.
Parliamentary analysis
As collective decisions, we can't provide breakdown analysis for agreements.
Agreements may represent unanimous decisions, or not opposed where an outcome is predetermined and time can be spent elsewhere.
Motion
Motion type: Other(?)
I beg to move, That this House notes that survival rates for brain tumours have seen little improvement in decades and that brain tumours remain the biggest cancer killer of children and adults under 40;
expresses concern at the limited availability of clinical trials for brain tumour patients;
calls on the Government to set out a clear plan to increase survival rates, including accelerating access to clinical trials and innovative therapies;
further calls on the Government to support the expansion of tissue freezing and storage to enable research and the development of new treatments;
and also calls on the Government to ensure the timely deployment of the research funding committed in 2018 through the National Institute for Health and Care Research for brain tumour research.
Annotations
No annotations for this decision.